Year archive

Oculis Holding AG — 2026 filings

All 36 regulatory filings released by Oculis Holding AG (OCS) in 2026, sourced directly from the official regulator.

36 Filings

2026 Period

2026 filings (36)

Filing	Released	Lang
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities Director's Dealing	2026-05-15	English
Oculis birtir niðurstöður aðalfundar 2026 og tilkynnir um kjör Gregory D. Perry í stjórn félagsins Declaration of Voting Results & Voting Rights Announcements	2026-05-14	Icelandic
Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors Declaration of Voting Results & Voting Rights Announcements	2026-05-14	English
6-K Foreign Filer Report	2026-05-14	English
Oculis birtir uppgjör fyrir fyrsta ársfjórðung 2026 og kynnir áfanga í rekstri félagsins Interim / Quarterly Report Q1 2026	2026-05-11	Icelandic
Oculis Reports Q1 2026 Financial Results and Provides Company Update Earnings Release Q1 2026	2026-05-11	English
Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial Regulatory Filings	2026-05-07	English
Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting Regulatory Filings	2026-05-05	English
Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting Regulatory Filings	2026-05-01	English
Oculis birtir boð á aðalfund Proxy Solicitation & Information Statement	2026-04-21	Icelandic
Oculis Publishes Invitation to the Annual General Meeting AGM Information	2026-04-21	English
Oculis lýkur síðustu eftirfylgniheimsókn í fasa 3 DIAMOND rannsóknaráætluninni með OCS-01 augndropum til meðferðar á sjónhimnubjúg af völdum sykursýki Regulatory Filings	2026-04-20	Icelandic
Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema Regulatory Filings	2026-04-20	English
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities Director's Dealing	2026-04-08	English
Oculis to Participate in Upcoming Investor Conferences Investor Presentation	2026-04-07	English
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis Regulatory Filings	2026-03-31	English
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities Director's Dealing	2026-03-27	English
SCHEDULE 13G/A - Oculis Holding AG (0001953530) (Subject) Major Shareholding Notification	2026-03-27	English
Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting Regulatory Filings	2026-03-16	English
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities Director's Dealing	2026-03-16	English
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities Director's Dealing	2026-03-13	English
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities Report Publication Announcement	2026-03-11	English
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities Director's Dealing	2026-03-06	English
Oculis Publishes 2025 Consolidated Financial Statements Report Publication Announcement	2026-03-05	English
Oculis to Participate in Upcoming Investor Conferences Regulatory Filings	2026-03-05	English
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities Director's Dealing	2026-03-04	English
20-F - OCULIS HOLDING AG (0001953530) (Filer) Annual Report FY 2025	2026-03-04	English
Oculis birtir uppgjör fyrir fjórða ársfjórðung og árið 2025 og kynnir áfanga í rekstri félagsins Earnings Release Q4 2025	2026-03-03	Icelandic
Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update Earnings Release Q4 2025	2026-03-03	English
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities Director's Dealing	2026-02-27	English
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated Director's Dealing	2026-02-18	English
Oculis Appoints Katie Kazem as Chief Legal Officer Board/Management Information	2026-02-17	English
Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference Regulatory Filings	2026-01-08	English
Oculis tilkynnir um að Matvæla- og lyfjastofnun Bandaríkjanna (FDA) hafi veitt Privosegtor stöðu byltingarkennds meðferðarlyfs til meðhöndlunar á sjóntaugabólgu Regulatory Filings	2026-01-06	Icelandic
Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis Regulatory Filings	2026-01-06	English
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities Director's Dealing	2026-01-05	English